{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:04:29Z","timestamp":1789250669872,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL143156"],"award-info":[{"award-number":["K23HL143156"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jacep.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T14:27:31Z","timestamp":1570026451000},"page":"1384-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation"],"prefix":"10.1016","volume":"5","author":[{"given":"Benjamin A.","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Ballew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lippmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2019.07.011_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib2","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2019.07.011_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2011.01.010","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"57","author":"Wann","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2019.07.011_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.164.1.55","article-title":"National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation","volume":"164","author":"Fang","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/01.STR.31.4.822","article-title":"Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation","volume":"31","author":"Gage","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.jacep.2019.07.011_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.160.1.41","article-title":"Why do patients with atrial fibrillation not receive warfarin?","volume":"160","author":"Bungard","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","article-title":"Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"168","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2019.07.011_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/1755-5922.12129","article-title":"Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation","volume":"33","author":"Steinberg","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacep.2019.07.011_bib11","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/CIRCULATIONAHA.112.109330","article-title":"Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation","volume":"126","author":"Piccini","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2019.07.011_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCOUTCOMES.111.962688","article-title":"Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007","volume":"5","author":"Piccini","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacep.2019.07.011_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.hrthm.2012.04.031","article-title":"Pharmacotherapy in Medicare beneficiaries with atrial fibrillation","volume":"9","author":"Piccini","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacep.2019.07.011_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/pds.3290","article-title":"Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database","volume":"21","author":"Goldberg","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacep.2019.07.011_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jacep.2019.07.011_bib16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jacep.2019.07.011_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.jacep.2019.07.011_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.jacep.2019.07.011_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archinte.1995.00430030071008","article-title":"Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly","volume":"155","author":"McCrory","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ahj.2013.12.014","article-title":"Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"167","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2019.07.011_bib21","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2019.07.011_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacep.2019.07.011_bib23","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2019.07.011_bib24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2019.07.011_bib25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacep.2019.07.011_bib26","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial","volume":"66","author":"Sherwood","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2019.07.011_bib27","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2019.07.011_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2019.07.011_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2017.03.007","article-title":"The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial","volume":"189","author":"Holmes","year":"2017","journal-title":"Am Heart J"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X19305407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X19305407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:27:39Z","timestamp":1762500459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X19305407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2405500X19305407"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2019.07.011","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2019.07.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}